On April 23rd, Medigen Vaccine Biologics Corp. (MVC) and GC Pharma (GCC) entered an exclusive distribution agreement for GCC's quadrivalent influenza vaccine, GC Flu Quadrivalent, in Taiwan. GCFlu Quadrivalent was first licensed by South Korean Authority (MFDS) in 2015. It is the second WHO prequalified seasonal influenza vaccine to cover against four influenza strains.
MVC will exclusively commercialize and distribute the vaccine using GC Pharma's final product, or perform fill/finish and distribute the vaccine using MVC's own brand. This new partnership supports MVC's strategy to provide people more prophylactic treatment against infectious diseases.
【About Medigen Vaccine Biologics Corp., MVC 】
MVC is a cell-based biopharmaceutical company focusing on the development and production of vaccines and biologics. MVC's business partners include US NIH, US CDC, WHO/UCAB, Taiwan CDC, and Taiwan National Health Research Institute. MVC's pipeline includes enterovirus A71 vaccine, dengue vaccine, H7N9 influenza mock-up vaccine, biosimilar palivizumab, and other niche products including seasonal flu vaccine, snake antivenom and BCG.
【About GC Pharma, GCC】
GC Pharma (formerly known as Green Cross Corporation, KRX：006280) is a biopharmaceutical company that delivers life-saving and life-sustaining protein therapeutics and vaccines. Headquartered in South Korea, GC Pharma is the largest plasma protein product manufacturer in Asia and has been dedicated to quality healthcare solutions for more than half a century. Green Cross Corporation updates its corporate brand as GC Pharma in early 2018. Green Cross Corporation remains the company's registered, legal name. For more information, please visit www.globalgreencross.com